Intervet International B.v.

Intervet Inc.

Akzo Nobel N.v.

Ruud Philip Antoon Maria Segers

Carla Christina Schrier

Antonius Arnoldus Christiaan Jacobs

Paul Vermeij

Mark A Mogler

Erin Linn Strait

Joachim Frey

Maarten Hendrik Witvliet

Pravina Kitikoon

Johannes Franciscus Van Den Bosch

Melanie Sno

Jeremy Mark Wells

Erwin Van Den Born

Selma Marianne Hensen

Dieter Mark Bulach

Peer Lyng Frandsen

Henricus Leo Bernardus Maria Klaasen

Nicolas Robin Waterfield

Luc Grisez

Erik Cox

Chow Yong Ng

Supraja Puttamreddy

Basav Nagaraj

Ben Adler

Paul Antony Cullen

Scott Adam James Coutts

The present invention provides vectors and/or nucleic acid constructs that encode one or more influenza A virus neuraminidase (NA) antigens. The present invention also provides vaccine against influenza A virus comprising such vectors and/or nucleic acid constructs. The present invention further provides methods of making and using the vaccines alone, or in combination with other protective agents.

Swine influenza a virus vaccine

The present invention relates to vaccination against animal pathogens using alphavirus-replicon RNA particles and oil adjuvants. To a vaccine, and a kit of parts comprising the replicon particles and the oil adjuvant. Also to methods and uses of making and using the vaccine and the components of the kit.

Vaccination with replicon particles and oil adjuvant

The present invention relates to a method of vaccination. Specifically the invention regards to a prime-boost vaccination regimen for protecting a target animal against infection or disease caused by a virus, wherein the vaccination regimen comprises the administration to said target animal of a vaccine comprising a live attenuated form of said virus, followed by the administration to said target animal of a vaccine comprising an RP encoding one or more antigens from said virus.

Prime-boost vaccination regimen

The present invention pertains to a vaccine comprising an ORF2 encoded protein of porcine circo virus 2 (PCV2) and a pharmaceutically acceptable carrier, for use in a method to protect a pig against an infection with porcine circo virus type 2 by administering the vaccine to the pig, wherein the vaccine comprises less than 20 &#x3bc;g per dose of the ORF2 encoded protein, the protein being of a porcine circo virus of genotype 2b.

Vaccine comprising a PCV2 ORF2 protein of genotype 2b

The present invention pertains to the use of a non-live carbohydrate containing composition, the carbohydrate being also found in livecells in association with the outer cell membrane of these cells, for the manufacture of a vaccine for protection against an infection with, the vaccine being in a form suitable for systemic administration.

[object Object]

The present invention pertains to a vaccine comprising in combination non-live antigens of, ofand Porcine circo virus, and a pharmaceutically acceptable carrier. The invention also pertains to a kit comprising a first container having contained therein non-live antigens of, one or more other containers having contained thereinand Porcine circo virus antigens and instructions for mixing the antigens of, and Porcine circo virus to formulate one combination vaccine suitable for systemic vaccination.

The present invention pertains to the use ofantigens corresponding tobacteria of a predetermined serotype in the manufacture of a vaccine for administration to a sow or gilt, to protect a piglet through the intake of colostrum of the said sow or gilt, against a disorder arising frombacteria of a serotype other than the predetermined one. The invention also pertains toantigens for use in the manufacture of such a vaccine.

The present invention relates to the use of bacteria of the speciesfor the manufacture of a vaccine, to methods for the production of such vaccines, to bacteria of the speciesfor use in a vaccine and to methods for the combating ofinfection in fish.

The present invention relates to nucleic acid sequences encoding a 30 kDlipoprotein and to parts of such nucleic acid sequences that encode an immunogenic fragment of such lipoproteins, and to DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof. The invention also relates to a 30 kDlipoprotein and immunogenic parts thereof encoded by such sequences. Furthermore, the present invention relates to vaccines comprising such nucleic acid sequences and parts thereof, DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof, lipoproteins or immunogenic parts thereof and antibodies against such lipoproteins or immunogenic parts thereof. Also, the invention relates to the use of said lipoproteins in vaccines and for the manufacture of vaccines. Moreover, the invention relates to the use of said nucleic acid sequences, lipoproteins or antibodies for diagnostic or vaccination purposes. Finally the invention relates to diagnostic kits comprising such a nucleic acid, lipoprotein or antibodies against such lipoprotein.

The present invention relates to live attenuated bacteria of the genus that have a mutation in an apxIV gene such that no functional ApxIV toxin can be produced. The invention also relates to methods for the production of such bacteria. Also vaccines comprising such bacteria and methods for the production of such vaccines are part of the invention. The invention further relates to subunit vaccines comprising an ApxIV toxin, to methods for the production of such vaccines and to methods for the protection of animals against infection with bacteria of the genus In addition, the invention relates to the promotor of the apxIV gene. Finally, the invention relates to diagnostic test for the selective diagnosis of infections and to diagnostic tests discriminating between field strains and vaccine strains.

Actinobacillus pleuropneumoniae subunit vaccine

The present invention relates to live attenuated RTX-toxin producing bacteria of the family Pasteurellaceae, of which the attenuation is due to the fact that they produce RTX toxin in a non-activated form. The invention also relates to vaccines for the protection of mammals against infection with RTX-toxin producing bacteria of the family Pasteurellaceae, and to methods for the preparation of said live attenuated bacteria and vaccines.

Live attenuated RTX-producing bacteria of the family pasteurellaceae

The present invention relates to detoxified immunogenic derivatives of &bgr;-toxin or an immunogenic fragment thereof that have as a characteristic that they carry a mutation in the &bgr;-toxin amino acid sequence, not found in the wild-type &bgr;-toxin amino acid sequence. The invention also relates to genes encoding such &bgr;-toxins, as well as to expression systems expressing such &bgr;-toxins. Moreover, the invention relates to bacterial expression systems expressing a native &bgr;-toxin. Finally, the invention relates to vaccines based upon detoxified immunogenic derivatives of &bgr;-toxin, and methods for the preparation of such vaccines.

Growing community of inventors

Boxmeer, Netherlands

Ruud Philip Antoon Maria Segers